After 30 days, peptide assay shows 78% remaining potency (hypothetical, based on similar peptide degradation curves)
Semaglutide is a GLP-1-only agonist, while tirzepatide activates both GLP-1 and GIP receptors simultaneously, producing stronger appetite suppression and metabolic effects in many patients
They typically describe one patient, and therefore do not demonstrate comprehensive proof of a drug effect for all users, only a one-off situation where this has occurred
doi: 10.1111/ijcp.13731 Summary Keywords body weight, glycated hemoglobin (HbA 1c ), efficacy, glucagon-like peptide-1 receptor agonist (GLP-1RA), oral, semaglutide, subcutaneous, type 2 diabetes Citation Meier JJ (2021) Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
Oral GLP-1 medications generally produce somewhat less weight loss than injectable versions in clinical data (16.6% vs